Biokinetics and Dosimetry of 188Re-anti-CD20 in Patients with Non-Hodgkin's Lymphoma: Preliminary Experience

Archives of Medical Research

Volumn 39, Issue 1, 2008, Pages 100-109

  Torres García, Eugenio ^a,b   Ferro Flores, Guillermina ^a   Arteaga de Murphy, Consuelo ^c   Correa González, Luis ^d   Pichardo Romero, Pablo A ^d  

^a INSTITUTO NACIONAL DE INVESTIGACIONES NUCLEARES   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MÉXICO   (Mexico)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^d HOSPITAL DE ONCOLOGÍA   (Mexico)

Author keywords

188Re rituximab; Rhenium 188; Rhenium 188 labeled anti CD20

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIBODY RE 188; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; UNCLASSIFIED DRUG; 188RE ANTI CD20 MONOCLONAL ANTIBODY; 188RE-ANTI-CD20 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CASE REPORT; CONTROLLED STUDY; DOSIMETRY; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HUMAN; KIDNEY CLEARANCE; MALE; NONHODGKIN LYMPHOMA; RADIATION DOSE; RADIOACTIVITY; RADIOIMMUNOTHERAPY; WHOLE BODY IMAGING; CLINICAL TRIAL; MIDDLE AGED; WHOLE BODY COUNTING;

ADOLESCENT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; WHOLE BODY IMAGING; WHOLE-BODY COUNTING;

EID: 36549061016     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2007.06.023     Document Type: Article

References (42)

1. Hainsworth J.D. Monoclonal antibody therapy in lymphoid malignancies. Oncologist 5 (2000) 376-384
2. Delgado J., Matutes E., Morilla A.M., Morilla R.M., Owusu K.A., Rafiq-Mohammed F., et al. Diagnostic significance of CD20 and FMC7 expression in B-cell disorders. Am J Clin Pathol 120 (2003) 754-759
3. Hernandez M.C., and Knox S.J. Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 59 (2004) 1274-1287
4. Tobinai K., Kobayashi Y., Narabayashi M., Ogura M., Kagami Y., Morishima Y., et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 study group. Ann Oncol 9 (1998) 527-534
5. Multani P.S., and Grossbard M.L. Monoclonal antibody-based therapies for hematologic malignancies. J Clin Oncol 16 (1998) 3691-3710
6. Hainsworth J.D. Rituximab as first-line systemic therapy for patients with low-grade lymphoma. Semin Oncol 27 (2000) 25-29
7. Czuczman M.S., Grillo-Lopez A.J., White C.A., Saleh M., Gordon L., LoBuglio A.F., et al. Treatment of patients with low grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17 (1999) 268-276
8. Saigo K., Okumachi Y., Kondo S., Chinzei T., Okamura A., Takenokuchi M., et al. Rituximab combined with small dose of melphalan for a refractory follicular lymphoma patient. Leuk Lymphoma 47 (2006) 353-356
9. Friesen C., Lubatschofski A., Kotzerke J., Buchmann I., Reske S.N., and Debatin K.M. Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cells. Eur J Nucl Med Mol Imaging 30 (2003) 1251-1261
10. Davies T.A., Kaminski M.S., Leonard J.P., Hsu F.J., Wilkinson M., Zelenetz A., et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 10 (2004) 7792-7798
11. Johnson T.A., and Press O.W. Synergistic citotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas. Int J Cancer 85 (2000) 104-112
12. DeNardo G. Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs). Sem Nucl Med 35 (2005) 202-211
13. Malik E.J. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med 43 (2002) 1507-1529
14. Macklis R.M., and Pohlman B. Radioimmunotherapy for non-Hodgkin's lymphoma: a review for radiation oncologists. Int J Radiat Oncol Biol Phys 66 (2006) 833-841
15. Meredith R.F. Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 66 (2006) S23-S29
16. Chesson B. Bexxar (Corixa/GlaxoSmithKline). Curr Opin Investig Drugs 3 (2002) 165-170
17. Gordon L.I., Witzig T., Molina A., Czuczman M., Emmanouilides C.H., Joyce R., et al. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 5 (2004) 98-101
18. Ansell S.M., Schilder R.J., Pieslor P.C., Gordon L.I., Emmanouilides C.H., Vo K., et al. Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature. Clin Lymphoma 5 (2004) 202-204
19. Wiseman G.A., and Witzig T. Yttrium90 (90Y) Ibritumomab tiuxetan (Zevalin) induces long term durable responses in patients with released or refractory B-cell non-Hodgkin's lymphoma. Cancer Biother Radiopharmaceut 20 (2005) 185-188
20. Friedberg J.W., and Fisher R.I. Iodine-131-tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther 4 (2004) 18-26
21. 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience. Eur J Nucl Med Mol Imaging 32 (2005) 1225-1233
22. 131I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes. J Nucl Med 45 (2004) 1059-1064
23. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352 (2005) 441-449
24. Hagenbeek A., and Lewington V. Report of a European consensus workshop to develop reccomendations for the optimal use of 90Y-ibritumomab tiuxetan (Zevalin) in lymphoma. Ann Oncol 16 (2005) 786-792
25. 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 43 (2002) 267-272
26. Davies A.J., Rohatiner A.Z.S., Howell S., Britton K.E., Owens S.E., Micallef I.N., et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 22 (2004) 1469-1479
27. Vose J.M., Wahl R.L., Saleth M., Rohatimer A.Z., Knox S.J., Radford J.A., et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 18 (2000) 1316-1323
28. Bunjes D., Buchmann I., Duncker C., Seitz U., Kotzerke J., Wiesneth M., et al. Rhenium-188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukaemia or myelodysplastic syndrome: results of a phase I-II study. Blood 98 (2001) 565-572
29. 90Y-labeled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. Br J Haematol 130 (2005) 604-613
30. 188Re-anti-CD20 for the treatment of non-Hodgkin's lymphoma. Nucl Med Commun 26 (2005) 793-799
31. 131I-tositumomab biodistribution in a phantom model. J Nucl Med Technol 34 (2006) 224-227
32. Siegel J.A., Thomas S.R., Stubbs J.B., Stabin M.G., Hays M.T., Koral K.F., et al. MIRD Pamphlet No. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 40 (1999) 37S-61S
33. Jonsson L., Ljungberg M., and Strand S.E. Evaluation of accuracy in activity calculations for the conjugate view method from Monte Carlo simulated scintillation camera images using experimental data in an anthropomorphic phantom. J Nucl Med 46 (2005) 1679-1686
34. Stabin M.G., Sparks R.B., and Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46 (2005) 1023-1027
35. Rutar F.J., Augustine S.C., Kaminski M.S., Wahl R.L., Siegel J.A., and Colcher D. Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members. Clin Lymphoma 2 (2001) 164-172
36. Harwood S.J., Gibbons L.K., Goldner P.J., Webster W.B., and Carroll R.G. Outpatient radioimmunotherapy with Bexxar. Closed, clean air reservoir minimizes personnel radiation exposure. Cancer 94 (2002) 1358-1362
37. 131I-labeled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma. Eur J Nucl Med 29 (2002) 1276-1282
38. 131I-rituximab show patient-specific stable biodistribution and tissue kinetics. Eur J Nucl Med Mol Imaging 32 (2005) 943-951
39. Silverman D.H., Delpassand E.S., Torabi F., Goy A., McLaughlin P., and Murray J.L. Radiolabeled antibody therapy in non-Hodgkin's lymphoma: radiation protection, isotope comparisons and quality of the issues. Cancer Treat Rev 30 (2004) 165-172
40. Wahl R.L., Kroll S., and Zasadny K.R. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med 39 Suppl 8 (1998) 14S-20S
41. Kassis A.I., and Adelstein J. Considerations in the selection of radionuclides for cancer therapy. In: Welch M.J., and Redvanly C.S. (Eds). Handbook of Radiopharmaceuticals, Radiochemistry and Applications (2003), Wiley & Sons, London 767-793
42. 131I-labeled anti-CD20. Phys Med Biol 51 (2006) N349-N356